What Lantern Pharma does

Lantern Pharma Inc. is a clinical-stage biopharmaceutical company founded in 2013 and headquartered in Dallas, Texas, publicly traded on NASDAQ under ticker LTRN. The company pairs a proprietary AI/ML drug development platform called RADR® (Response Algorithm for Drug Positioning & Rescue) with a portfolio of precision oncology drug candidates. RADR® integrates over 200 billion oncology-focused data points, more than 200 advanced ML algorithms, 130,000+ patient records, and 8,163+ datasets across 438 cancer types through six automated workflow modules covering data ingest, preprocessing, feature selection, prediction, hypothesis generation/validation, and patient stratification/clinical trial design. Built on RADR®, the company commercially launched withZeta.ai in April 2026 as a multi-agentic AI co-scientist platform for rare cancer drug discovery, with introductory, academic, and commercial subscription tiers, and offers predictBBB.ai as a Large Quantitative Model web service for small-molecule developability profiling.

Name

Lantern Pharma

Legal name

Lantern Pharma Inc.

Website

https://lanternpharma.com

Company type

Public

Founded year

2013

Operating status

Operating

Headcount range

11–50 employees

Short description

Lantern Pharma is a clinical-stage biopharmaceutical company that uses its proprietary RADR® AI/ML platform to develop precision oncology drug candidates (LP-300, LP-184, LP-284, STAR-001) and commercializes AI subscription services to biopharma and academic customers.

Ownership category

akta.pro rank

Product category

Precision Oncology Pharmaceuticals / AI Drug Discovery

NAICS

Research and Development in Biotechnology (except Nanobiotechnology) (541714), Pharmaceutical Preparation Manufacturing (325412)

SIC

Pharmaceutical Preparations (2834), Services-Medical Laboratories (8071)

akta.pro primary industry

AI/ML-Enabled Biologic Discovery Platforms (computational design, in silico screening) (HLAAAIAE)

akta.pro secondary industry

Clinical Trial Informatics (EDC/CTMS/eCOA/eTMF) (HLAGAJAM)

Keywords

• Precision oncology therapeutics
• AI drug discovery platform
• Oncology clinical development
• Machine learning biomarker
• Pharmaceutical patent portfolio

Headquarters

HQ city

Dallas

HQ country

United States

HQ region

North America

Offices4 records

Markets served

GTM type

B2B

Offering type

Services

Cost components

Technology or R&D, Personnel, Operations, Marketing or Sales, Infrastructure

Revenue model

1. withZeta.ai Subscription Platform: Subscription-based AI co-scientist platform offered to pharma companies, academic medical centers, and biotech research groups with introductory, academic, and commercial tiers; represents a non-dilutive revenue stream for Lantern Pharma.
2. predictBBB.ai Subscription Service: Subscription-based Large Quantitative Model (LQM) web service that calculates 99 molecular features from a single SMILES string; integrated with withZeta.ai and offered for early pharma partnership integration into discovery workflows.
3. AI Center of Excellence Licensing & Co-Development: Bengaluru, India AI Center of Excellence expected to generate multiple revenue pathways through licensing, co-development programs, and specialized AI service engagements with global biopharma companies; planned to be cash flow neutral while scaling.
4. Strategic RADR® AI Collaborations: Co-development partnerships with biopharma (Actuate, Oregon Therapeutics, TTC Oncology) where Lantern provides AI-driven biomarker identification, patient stratification, and indication optimization in exchange for potential equity, milestone payments, and exclusive licensing rights (e.g., exclusive option to license TTC-352).
5. Clinical-Stage Oncology Drug Development (Future): Pipeline of three lead drug candidates (LP-300, LP-184, LP-284) and an ADC program across 12 cancer indications, with potential future revenue from drug sales, out-licensing, and milestone payments upon regulatory approval. Currently no approved drugs.

Pricing tiers

Go-to-market motion4 records

Distribution channels4 records

Core offering

Lantern Pharma is a clinical-stage biopharmaceutical company that develops precision oncology drug candidates and commercializes AI/ML software platforms for oncology drug discovery. Its core products include the RADR® AI platform, the withZeta.ai multi-agentic AI co-scientist subscription product, the predictBBB.ai large quantitative model web service, and a pipeline of precision oncology drug candidates (LP-300, LP-184, LP-284, LP-100, STAR-001) plus an ADC discovery program across 12 cancer indications.

Product overview

Lantern Pharma is a clinical-stage oncology pharmaceutical company that pairs a core AI/ML platform with a portfolio of precision small-molecule drug candidates. RADR® is the central proprietary platform — integrating 200+ billion oncology data points and 200+ ML algorithms across six automated workflow modules (Data Ingest, Data Processing & Curation, Feature Selection, Prediction, Hypothesis Generation/Validation/Feedback, and Patient Stratification & Clinical Trial Design) — which powers both internal drug development and external collaborations. Built on RADR®, withZeta.ai is a commercially available multi-agentic AI co-scientist for rare cancer drug discovery offered on subscription tiers, and predictBBB.ai is a Large Quantitative Model web service for blood-brain barrier permeability prediction that is fully integrated into withZeta.ai. The therapeutic pipeline consists of four small-molecule drug candidates — LP-300 (Phase 2 HARMONIC trial in NSCLC adenocarcinoma), LP-184 (Phase 1a complete, advancing into Phase 1b/2 across CNS and solid-tumor indications), LP-284 (Phase 1 in non-Hodgkin's lymphomas), and LP-100 (Phase 2 in mCRPC, out-licensed to Oncology Venture) — along with STAR-001 (FDA IND-cleared pediatric CNS cancer program through subsidiary Starlight Therapeutics) and an early-stage antibody-drug conjugate (ADC) program. Lantern also operates the Harmonic™ mobile companion app and an AI Center of Excellence in Bengaluru, India, and is preparing to spin off withZeta.ai as a standalone entity.

Differentiator

Problem solved

Functional benefit

Brands

• RADR®: Response Algorithm for Drug Positioning & Rescue — Lantern's proprietary integrated AI/ML platform leveraging over 200 billion oncology-focused data points and 200+ advanced ML algorithms for biomarker identification, patient stratification, and clinical trial design.
• withZeta.ai
• predictBBB.ai

Products and services

• RADR® Response Algorithm for Drug Positioning & Rescue — Lantern Pharma's proprietary integrated data analytics, experimental biology, and machine-learning platform that ingests 200+ billion oncology-specific data points across 8,163+ datasets and applies 200+ ML algorithms across six workflow modules to predict drug response, identify biomarkers, and stratify patients for oncology trials.
• withZeta.ai The world's first multi-agentic AI co-scientist platform for rare cancer drug discovery and development, built on RADR® and spanning 438 cancer types; integrates a rare cancer ontology, multi-database querying, and generative AI capabilities including molecular design and ADMET prediction; offered via introductory, academic, and commercial subscriptions, with ZetaSwarm™ and ZetaOmics™ capability tracks.
• predictBBB.ai Large Quantitative Model (LQM) web service that calculates 99 critical molecular features from a single SMILES string to predict blood-brain barrier permeability and small-molecule developability; five of Lantern's BBB permeability algorithms rank in the top 12 on the Therapeutic Data Commons leaderboard; fully integrated into withZeta.ai and offered as a subscription-based service with early pharma partnerships.
• LP-300 LP-300 (Disodium 2,2'-dithio-bis-ethane sulfonate, originally branded Tavocept®) is a small molecule with cysteine-modifying activity on select proteins (ALK) that modulates EGFR, MET, and ROS1 pathways and acts as a chemo-sensitizer and chemoprotectant; in Phase 2 HARMONIC™ trial in combination with carboplatin and pemetrexed for never-smoker NSCLC adenocarcinoma patients post-tyrosine-kinase-inhibitor treatment.
• LP-184 LP-184 (hydroxyureamethylacylfulvene) is a next-generation acylfulvene prodrug synthetically lethal in tumors with defective HR/NER DNA repair pathways and selectively activated by PTGR1; Phase 1a enrollment completed with a 48% clinical benefit rate; advancing into biomarker-guided Phase 1b/2 trials across CNS cancers (GBM, ATRT, brain mets), TNBC, bladder, pancreatic, and other solid tumors, with an FDA Fast Track Designation in glioblastoma and multiple Rare Pediatric Disease Designations.
• LP-284 LP-284 is the stereoisomer (enantiomer) of LP-184 and a member of the new generation of acylfulvenes, with distinct anti-tumor activity in hematological cancers including mantle cell lymphoma (MCL), double-hit lymphoma, and multiple myeloma; Phase 1 trial ongoing in relapsed/refractory B-cell NHL and solid tumors; granted three FDA Orphan Drug Designations (MCL, HGBL with MYC/BCL2 rearrangements, soft tissue sarcomas) and EU patent allowance through early 2039.
• LP-100 LP-100 (6-hydroxymethylacylfulvene) is a monofunctional covalent DNA binder that exploits cancer cells' deficiency in DNA repair mechanisms (e.g., ERCC2/3 mutations) and is currently in an active Phase 2 trial in Denmark for metastatic castration-resistant prostate cancer (mCRPC) through Oncology Venture, with additional potential in bladder and ERCC-mutated prostate cancers.
• STAR-001 STAR-001 is a precision oncology compound being developed by Lantern Pharma's wholly owned subsidiary Starlight Therapeutics; FDA IND-cleared in March 2026 for a planned Phase 1 pediatric clinical trial evaluating STAR-001 alone and in combination with spironolactone across relapsed/refractory CNS malignancies (ATRT, DIPG, GBM, medulloblastoma, ependymoma) in 18 to 42 patients aged 1 to 17 across approximately 15 centers in the US, Canada, and Israel via POETIC.
• ADC Program Early-stage antibody-drug conjugate (ADC) program targeting select solid tumors; developed with AI-driven target identification and cryptophycin-loaded payload optimization in collaboration with Bielefeld University, supported by Lantern's RADR® AI platform for in-silico ADC target discovery.

Quantifiable outcome

• 70%-80% reduction in time to move drugs into clinical testing
• +9 more outcomes

Named customers11 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability11 records

Feature6 records

Partnerships

19 partnerships are on record, tiered media sponsorship partner, technology infrastructure partner, flagship ai collaboration partner, major ai collaboration partner, major academic research collaborator, flagship academic research collaborator, international academic partner, international data partner, major academic cancer center partner, flagship government research partner, major clinical trial network partner, academic research collaborator, wholly owned subsidiary for cns oncology, investor relations and gtm partner and specialized research collaborator.

• New to The Street (sponsored programming)media sponsorship partnerGTM or Marketing Partner · 9 April 2026Sponsored commercial segments on Bloomberg Television across US, MENA, and Latin America (Episodes 698, 710, 753) featuring Lantern Pharma executive interviews on AI-driven oncology and precision-medicine drug development; reaches over 4.74-5.6 million YouTube subscribers combined.
• Code Oceantechnology infrastructure partnerTechnology or Integration · 1 November 2023Partnered with Code Ocean on computational oncology drug development workflows; supporting RADR® platform computational infrastructure.
• Actuate Therapeuticsflagship ai collaboration partnerStrategic or Co-development Partner · 1 May 2021Lantern is accelerating the development of Actuate Therapeutics' drug candidate Elraglusib (9-ING-41) using AI insights produced by RADR®. RADR® has predicted patient response with accuracy exceeding 88%, identifying a subset of metastatic melanoma patients resistant to PD-1 therapies who may benefit from Elraglusib. The collaboration includes new data integration (RNA, ctDNA, protein biomarkers) shaping an upcoming Phase 2 clinical trial design. Lantern received equity in Actuate under the strategic partnership.
• Oregon Therapeuticsmajor ai collaboration partnerStrategic or Co-development PartnerLantern is optimizing the development of Oregon Therapeutics' first-in-class protein disulfide isomerase (PDI) inhibitor drug candidate XCE853 in novel and targeted cancer indications. Lantern is leveraging RADR® AI platform to uncover biomarkers and efficacy-associated signatures across solid tumors to aid in precision development. XCE853 is being developed in drug-resistant ovarian and pancreatic cancer, hematological cancers, and pediatric CNS cancers.
• TTC Oncologymajor ai collaboration partnerStrategic or Co-development PartnerLantern is accelerating the development of TTC Oncology's drug candidate TTC-352 using AI insights produced by RADR®. TTC-352 is a Phase 2 clinical trial-ready drug candidate designed for metastatic ER+ breast cancer. The collaboration includes biomarker/gene signature identification for patient selection in an upcoming Phase 2 trial, mechanism of action characterization, and exploration of additional indications. The terms grant Lantern Pharma an exclusive right to license TTC-352 along with collaboration IP during an exclusive option period.
• Fox Chase Cancer Centermajor academic research collaboratorStrategic or Co-development PartnerAcademic research collaborator on LP-184 development across multiple indications including pancreatic cancer (with Champions Oncology), CNS brain metastases, bladder cancer, and GBM. Co-developed preclinical efficacy data and translational research.
• Johns Hopkins School of Medicineflagship academic research collaboratorStrategic or Co-development PartnerAcademic research collaborator on LP-184 development for CNS Cancers, glioblastoma, and ATRT (atypical teratoid rhabdoid tumor). Co-developed preclinical data leading to Rare Pediatric Disease and Orphan Drug Designations.
• Georgetown Universitymajor academic research collaboratorStrategic or Co-development PartnerAcademic research collaborator on LP-184 prostate cancer positioning in DNA damage repair deficient prostate cancer. Co-developed AACR 2021 presentation and biomarker studies.
• UT Health San Antonio - Greehey Children's Cancer Research Institutemajor academic research collaboratorStrategic or Co-development PartnerAcademic research collaborator on LP-184 development for pediatric brain cancers program. Co-developing preclinical evidence supporting rare pediatric disease designations.
• Danish Cancer Society Research Centerinternational academic partnerStrategic or Co-development PartnerAcademic partner providing large genomic cancer data sets and collaborating on drugs for NER-deficient tumors. Listed in partnering section as a partner with novel cancer cell lines, organoid and PDX models.
• Genomics Englandinternational data partnerStrategic or Co-development PartnerPartner providing large genomic cancer data sets for AI-driven analysis via RADR® platform. Listed in Lantern's academic partner ecosystem.
• Uppsala Universityinternational academic partnerStrategic or Co-development PartnerAcademic partner providing large genomic cancer data sets and collaborating on RADR®-enabled drug development.
• Georgetown Lombardi Comprehensive Cancer Center (GCCRI)major academic cancer center partnerStrategic or Co-development PartnerAcademic medical center partner providing large genomic cancer data sets and collaborating on RADR®-enabled drug development.
• National Cancer Institute (NCI)flagship government research partnerStrategic or Co-development PartnerExpanded oncology partnership with NCI in January 2022, leveraging RADR® AI platform for development of drug candidates and supporting clinical translation.
• POETIC (Pediatric Oncology Experimental Therapeutics Investigators' Consortium)major clinical trial network partnerImplementation/ SI/ Consulting PartnerPOETIC research network conducting the planned Phase 1 pediatric CNS cancer trial of STAR-001 across approximately 15 centers in Canada, Israel, and the US; enrolling 18-42 patients aged 1-17 with relapsed or refractory CNS malignancies.
• Bielefeld Universityacademic research collaboratorStrategic or Co-development PartnerCooperation with Bielefeld University on using AI in the development of novel antibody-drug conjugates (ADCs), including cryptophycin-loaded ADCs and expanding the repertoire of ADC targets with improved tumor selectivity.
• Starlight Therapeutics (wholly owned subsidiary)wholly owned subsidiary for cns oncologyStrategic or Co-development PartnerWholly owned subsidiary of Lantern Pharma developing STAR-001 (LP-184) for pediatric CNS cancers. Received FDA IND clearance in March 2026 for Phase 1 pediatric CNS cancer trial of STAR-001 alone and in combination with spironolactone.
• RedChip Companiesinvestor relations and gtm partnerGTM or Marketing PartnerInvestor relations partner hosting multiple virtual investor conferences (April 16, 2026 Biotech Innovation Conference) and investor presentation sessions (withZeta.ai live demo April 30, 2026). Provides direct investor access and visibility for Lantern Pharma to retail and institutional investors.
• Champions Oncologyspecialized research collaboratorStrategic or Co-development PartnerCollaborator on LP-184 pancreatic cancer development providing tumor models and translational research expertise.

Scale indicators20 records

Recent moves8 records

Expansion highlights8 records

Emerging players

• Compugen: AI-enabled immuno-oncology company using computational platforms to identify novel drug targets and develop therapeutic antibodies. Comparable in using AI/computation for target discovery and clinical positioning; differs in therapeutic modality (antibodies vs Lantern's small molecules and ADCs).
• BenevolentAI: AI-augmented drug discovery company applying knowledge graphs and machine learning to biomedical research. Comparable in offering AI tools to pharma research teams and pursuing an internal pipeline; partial overlap with RADR/withZeta.ai in biomarker-driven drug repositioning.
• Black Diamond Therapeutics: Clinical-stage precision oncology company applying a computational platform to discover allosteric and orthosteric mutation-targeted therapies. Comparable as a small-cap AI-influenced oncology peer with a focus on genomically defined patient populations analogous to Lantern's RADR-stratified trials.
• Atomwise: AI-driven small-molecule discovery company focused on structure-based drug design through proprietary algorithms. Adjacent competitor to predictBBB.ai in molecular property prediction, though smaller scale and more partnership-dependent than Lantern's vertically integrated pipeline approach.
• Insilico Medicine: AI-driven drug discovery company with clinical-stage programs including in oncology and fibrosis. Comparable AI-first discovery approach with similar end-to-end platform-plus-pipeline structure; competitive overlap on rare cancer and biomarker-guided indications.

Broad incumbents

• Cyclacel Pharmaceuticals: Clinical-stage oncology biopharma developing small-molecule CDK inhibitors for hematological and solid tumors. Comparable as a small-cap clinical-stage oncology peer with limited cash runway; lacks Lantern's AI platform layer but competes in similar biomarker-stratified patient populations.

Direct peers

• Schrödinger, Inc. Computational chemistry and AI-driven drug discovery platform serving pharma clients and advancing an internal pipeline. Direct competitor to Lantern's withZeta.ai/predictBBB.ai subscription offerings with broader therapeutic scope; comparable on subscription-AI business model and platform-plus-pipeline structure.
• Recursion Pharmaceuticals: Clinical-stage AI-driven drug discovery company combining high-throughput biology with machine learning to develop precision therapeutics. Closest peer to Lantern given shared AI-first platform approach to pharma R&D, although Recursion's scale and platform breadth exceed Lantern's oncology focus.
• Exscientia: AI-driven precision medicine company with patient-derived data, active pharma partnerships, and an internal clinical pipeline. Comparable to Lantern as an AI-native drug discovery peer; differs in its emphasis on phenotypic patient data rather than genomic/transcriptomic biomarker signatures.

Regional players

• XtalPi: China-based AI drug discovery company combining quantum physics, AI, and robotics for small-molecule discovery. Comparable in computational chemistry tooling (e.g., ADMET/BBB modeling analogous to predictBBB.ai), though serving primarily Asia-Pacific biopharma customers.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat6 records

Key risks6 records

Key highlights7 records

Customer concentration

• Xx.com/lanternpharma
• YouTubeyoutube.com/channel/UC8ObRZsh1IxRSwelXqZ7o0w
• LinkedInWww.LinkedIn.com/company/lanternpharma

Revenue estimate

Valuation estimate

Number of profiles

Profiles6 records

Subsidiaries1 record

Funding overview

Funding rounds9 records

Investors3 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Lantern Pharma